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The use of unactivated blood for hemocompatibility testing is essential to obtain reliable results.
Here, the authors study the influence of heparinized whole blood storage time and temperature on
blood activation and evaluate the importance of initiating hemocompatibility tests within 4 h of
blood collection. Blood from healthy volunteers was collected and analyzed with minimal delay,
after 30 min and after 60 min of storage at room temperature, 30 or 37 C. In addition, blood was
analyzed after 1, 2, or 4 h of storage at room temperature. Platelet count, mean platelet volume,
platelet binding capacity to collagen and thromboxane B2 were measured to assess platelet
function, complement complex C5b-9 and elastase were measured to assess activation of the
inflammatory response system, and thrombin-antithrombin III was measured to assess activation of
the coagulation system. Furthermore, free hemoglobin was measured in platelet poor plasma as an
indicator for red blood cell damage. The authors found that storage at 30 C significantly increased
platelet and coagulation activity after 60 min and storage at 37 C significantly increased platelet,
coagulation, and white blood cell activity after 60 min. Storage at room temperature significantly
decreased platelet binding to collagen after 4 h and increased platelet activity after 1 h onward and
white blood cell activity after 4 h. Their results show that short-term storage of heparinized whole
blood significantly influences biomarkers over time, especially at 30 and 37 C compared to room
temperature. However, blood stored at room temperature for 4 h is also affected. In particular, pla-
telet function and white blood cell activity are significantly influenced after 4 h of stationary stor-
age at room temperature; therefore, the authors propose that hemocompatibility tests should be
initiated well within 4 h of blood collection, preferably within 2 h. VC 2016 Author(s). All article
content, except where otherwise noted, is licensed under a Creative Commons Attribution (CC BY)
license (http://creativecommons.org/licenses/by/4.0/). [http://dx.doi.org/10.1116/1.4941850]
I. INTRODUCTION
The use of medical devices in the cardiovascular system
has increased the demand for evaluation of their effects on
blood. Direct contact of biomaterials with blood results in the
activation of platelets (PLTs), the coagulation system, com-
plement cascades and white blood cells.1 These cascades are
also activated during blood collection and storage before
hemocompatibility testing or before processing in the clinical
laboratory. Even with the use of inert storage containers,
blood activation can occur due to the absence of endothelium-
derived inhibitors. Due to irreversible activation of these cas-
cades, a loss of function can ultimately result in false negative
or positive data during analysis. Therefore, the stability and
functionality of blood samples are continuously discussed in
the clinical community, especially the lesion of stored
platelets.2,3
In order to obtain unbiased hemocompatibility results, it
is important to use unactivated blood which is as similar to
the clinical setting as possible.1 By using a clinical dose of
heparin (1.5 IU/ml), a dose often used during cardiovascular
procedures, blood coagulation can be prevented without
inactivating the cascades,1 which are needed for hemocom-
patibility testing.
Braune et al. stated that the total test duration should not
exceed 4 h to ensure an appropriate function of blood cells
and blood plasma proteins,4 since it is observed that blood
activation starts shortly after blood collection. Thus, blood
storage time and temperature between collection and initia-
tion of hemocompatibility tests could significantly influence
results of hemocompatibility testing. The ISO 10993-Part 4
standard advises that hemocompatibility tests should be per-
formed with minimal delay, usually within 4 h of blood col-
lection,5 without reference to valid data. Following this
standard, several hemocompatibility studies described initia-
tion of hemocompatibility tests within 4 h of blood collec-
tion.6,7 However, there are also numerous studies regarding
hemocompatibility testing without any note on the analysis
time. There are few studies describing the effects of short-
term storage on biomarkers. A previous study described the
influences of citrated whole blood- and platelet rich plasma
(PRP) storage times on platelet- morphology and function
and stated that platelet morphology and function, particularly
platelet reactivity to adherent or soluble agonists changed
rapidly outside the vascular system.8 Another study reported
the stability of complement biomarkers in whole blooda)Electronic mail: w.vanoeveren@haemoscan.com
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containing citrate or ethylenediaminetetraacetic acid
(EDTA) and described that C4d, C3a, factor Bb, C5a and
C5b-9 were stable at room temperature for up to 4 h and that
thawing at 37 C resulted in increased levels of complement
markers in serum and citrated plasma but not in EDTA
plasma.9 However, to our knowledge, there are no reports on
short-term stability of the key determinants of hemocompati-
bility in heparinized whole blood.
The purpose of this study was to obtain further insight into
the effects of storage time and temperature prior to hemocom-
patibility testing. Therefore, we analyzed platelet function,
inflammatory response, coagulation and hemolysis of whole
blood over time. Blood from healthy volunteers was collected
and analyzed with minimal delay and after 30- and 60 min of
storage at room temperature, 30 or 37 C. From these data, it
was concluded that storage at room temperature was most
preferable. Subsequently, the experiment was repeated with
storage times up to 4 h at room temperature.
II. MATERIALS AND METHODS
A. Experimental setup
During the first part of this study, blood was collected and
stored at room temperature (21–25 C), 30 or 37 C for up to
60 min. Key determinants of hemocompatibility were analyzed
and the effects of storage time and temperature were exam-
ined. These data clearly indicated that storage at room temper-
ature was preferable. Therefore, in the second part of the
study, whole blood was stored at room temperature for up to
4 h and the key determinants of hemocompatibility were ana-
lyzed and the effects of storage time were further examined. In
addition, concentrations of the generated activation markers:
Thromboxane B2 (TXB2), complement complex C5b-9, elas-
tase, thrombin-antithrombin III (TAT III) complex and free
hemoglobin (Hb) after stationary storage at room temperature
for 4 h were compared with the concentrations generated in
whole blood which had been in vitro circulated as previously
described.10 The in vitro circulations (Hemobile, HaemoScan
BV, Groningen, The Netherlands) were performed in polyvi-
nyl chloride (PVC) circuits at 37 C for 1 h.
B. Blood collection
For the analysis of storage up to 60 min at different tem-
peratures, fresh human blood was collected by venipunc-
ture with a 19 Gauge butterfly needle from six healthy
adult volunteers (age 23–26) with a female to male ratio of
1:1 and anticoagulated with 1.5 IU heparin/ml (Leo
Pharmaceutical Products BV, Weesp, The Netherlands). In
addition, fresh human blood was collected and anticoagu-
lated in the same manner from nine healthy adult volun-
teers (age 19–28) with a female to male ratio of 5:4 for
storage up to 4 h at room temperature. The in vitro circula-
tions were performed with fresh human whole blood from
six healthy volunteers which was collected and anticoagu-
lated as described above.
C. Storage
Heparinized whole blood was transferred to test tubes
(Cellstar
VR
Tubes, Greiner Bio-One GmbH, Frickenhausen,
Germany) with minimal delay, and in the first part of the
study, they were stored stationary at room temperature
(21–25 C), 30 or 37 C for 30 or 60 min. Additionally, in the
second part of the study, heparinized whole blood was stored
in the same manner at room temperature for 1, 2, or 4 h.
D. Platelet function
Whole blood was centrifuged at 79g for 5 min, and the
supernatant was used as PRP of which PLTs were counted
(cell counter Medonic CA 530, Medonic, Sweden). Platelet
count and mean platelet volume (MPV) were analyzed
(Medonic CA 530) on whole blood containing 5mM EDTA
(preventing any further blood activation) and PLT count
was corrected for the EDTA dilution. The remaining EDTA
containing whole blood was centrifuged at 13 400g for
1min, and the supernatant was used as platelet poor plasma
(PPP).
Collagen is well known for its PLT binding capability;
thus, binding of PLTs to collagen was used to assess PLT
function. The capacity of PLTs to bind to collagen was ana-
lyzed in collagen-coated microtiter plates immediately after
PRP was obtained. Collagen-coated microtiter plates were
TABLE I. Activation markers of whole blood stored at room temperature, 30 or 37 C.
Room temperature 30 C 37 C
Analyses 0min 30min 60min pa 30min 60min pa 30min 60min pa
PLT (10E9/L) 2516 64 2356 79 2336 56 0.583 2396 56 2276 57 0.400 2316 49 2276 42 0.307
MPV (fl) 9.286 0.479 9.236 0.709 9.206 0.666 0.517 9.306 0.583 9.076 0.843 0.273 9.476 0.662 9.186 0.126 0.101
PLT-Col (%) 7.556 3.77 6.866 4.51 12.306 6.44 0.173 7.666 4.46 10.16 5.83 0.379 7.806 5.45 12.126 8.64 0.292
TXB2 (ng/ml) 0.9666 1.33 2.486 1.86 1.206 0.410 0.721 3.126 2.28 7.286 3.93 0.025 1.716 2.08 5.066 2.71 0.044
C5b-9 (ng/ml) 1976 401 2426 522 1926 417 0.611 2966 640 2146 464 0.562 2946 636 2176 390 0.227
Elastase (lg/ml) 1.956 1.16 1.856 0.819 2.356 1.41 0.668 2.546 1.02 3.096 1.64 0.187 2.106 0.803 4.126 1.85 0.001
TAT III (lg/ml) 1.356 0.840 2.076 2.54 2.196 1.50 0.362 1.976 2.71 5.296 3.16 0.031 1.406 1.26 4.886 1.95 0.022
Free Hb (%) 0.0856 0.026 0.0936 0.074 0.0556 0.021 0.156 0.0436 0.026 0.0556 0.035 0.156 0.1186 0.054 0.1006 0.063 0.653
aPaired samples t-test between baseline (0min) and 60min of storage. PLT, platelet count; MPV, mean platelet volume; PLT-Col, platelet binding to collagen;
TXB2, thromboxane B2; C5b-9, complement complex C5b-9; TAT III, thrombin-antithrombin III complex; and Free Hb, free hemoglobin.
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obtained by incubation of 96 wells flat-bottom microtiter
plates (NUNC MaxiSorp
VR
, Thermo Scientific, Inc., Roskilde,
Denmark) with 100lg/ml bovine type I collagen (Collagen
solution from bovine skin, Sigma-Aldrich
VR
Co. LLC., St.
Louis, MO, USA) in 50mM sodium carbonate, pH 9.6 at
2–8 C overnight. After washing with phosphate-buffered sa-
line, pH 7.4 (PBS), PLT binding was achieved by incubating
PRP for 1 h at 37 C. After washing with PBS, bound PLTs
were analyzed based on the presence of acid phosphatase11,12
by incubating with 5mM 4-nitrophenylphosphatase in citrate
buffer þ1% (v/v) Triton X-100, pH 5.4, on a shaker for 1 h.
After addition of 1M sodium hydroxide, conversion of the
substrate was measured at 405 nm (PowerWave 200, Bio-Tek
Instruments, Inc., Winooski, VT, USA). Optical density was
related to PLT concentration using counted PLTs (Medonic
CA 530) as a standard curve and the percentage of bound
PLTs was determined.
Platelet activation leads to the activation of the arachi-
donic acid synthesis pathway to produce thromboxane A2.1
Thromboxane A2 is highly unstable and rapidly converted to
TXB2,13 i.e., TXB2 can be used as an indicator for PLT acti-
vation. Thromboxane B2 in PPP was analyzed by means of
an enzyme immunoassay (Cayman Chemical Company,
Michigan, USA), based on the competition between acetyl-
cholinesterase labeled TXB2 and sample TXB2. Conversion
of the substrate (Ellman’s reagent) was measured at 415 nm
(PowerWave 200).
E. Inflammatory response
Complement complex C5b-9 was analyzed as an indica-
tor for complement activation. Complement complex C5b-
9 in PPP was analyzed by means of an enzyme-linked im-
munosorbent assay (ELISA) based on a mouse anti human
C5b-9 capture antibody (DAKO, Glostrup, Denmark) and a
goat anti C5 detection antibody (Quidel, San Diego, CA,
USA).
Elastase was analyzed as an indicator for white blood cell
activation. Elastase in PPP was analyzed by means of
ELISA based on a capture antibody against human elastase
and a labeled antibody against alpha 1 antitrypsin (Affinity
Biologicals, Inc., Ancaster, Canada).
F. Coagulation
Thrombin-antithrombin III complex was analyzed to
determine thrombin formation, as an indicator for coagula-
tion activity. Thrombin-antithrombin III complex in PPP
was analyzed by means of ELISA, using antibodies of
Cedarlane Laboratories, Ltd. (Hornby, Canada).
G. Hemolysis
Free Hb was used as an indicator for hemolysis, i.e., red
blood cell damage, and was measured as described by
Harboe14 (PowerWave 200). Percentage of hemolysis was
determined by comparison with a 100% hemolysis sample.
H. Statistical analysis
For the statistical analysis of storage up to 4 h at room
temperature, interdonor- and day-to-day variations were
eliminated by normalizing all data to a percentage of the
baseline (% baseline). Paired samples t-test was performed
for all blood parameters to assess any significant difference
(p< 0.05) between the different storage times and the
FIG. 1. Influences of whole blood storage at room temperature, 30 or 37 C
on thromboxane B2, elastase and thrombin-antithrombin III release in
plasma during whole blood storage. (a) Thromboxane B2, (b) elastase and
(c) thrombin-antithrombin III. *p< 0.05 compared with the baseline
(0min).
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baseline. Normally distributed variables were reported as
mean þ one standard deviation.
III. RESULTS
A. Platelet function
Storage of whole blood at room temperature for up to
60min did not change PLT count, MPV, PLT-collagen bind-
ing, or TXB2 concentrations over time (Table I). Storage of
whole blood at 30 or 37 C for up to 60min did increase
TXB2 concentrations over time (Table I, Fig. 1). Storage of
whole blood at room temperature for up to 4 h did not affect
PLT count or MPV over time (Table II). However, PLT-
collagen binding decreased after 4 h (Table II, Fig. 2) and
TXB2 concentrations increased after 1 h (p¼ 0.005), 2 h
(p 0.000) and 4 h (p 0.000) (Table II, Fig. 2). Generated
TXB2 of whole blood stored at room temperature for 4 h cor-
responded to 9% of the generated TXB2 in PVC circuits that
circulated on the Hemobile (Table III).
B. Inflammatory response
Complement complex C5b-9 and elastase of whole
blood stored at room temperature, 30 or 37 C, for up to
60min did not change over time (Table I). Storage of whole
blood at 37 C for up to 60 min increased elastase over time
(Table I, Fig. 1). Generated complement complex C5b-9 of
whole blood stored at room temperature for 4 h corre-
sponded to 0.1% of the generated complement complex
C5b-9 in PVC circuits that circulated on the Hemobile
(Table III). However, complement C5b-9 did not change
over time (Table II). Generated elastase of whole blood
stored at room temperature for up to 4 h increased over
time (Table II, Fig. 2) and after 4 h corresponded to 87% of
the generated elastase in PVC circuits that circulated on the
Hemobile (Table III).
C. Coagulation
Thrombin-antithrombin III complex of whole blood
stored at room temperature for up to 60 min did not change
over time (Table I). Thrombin-antithrombin III complex of
whole blood stored at 30 or 37 C did increase over time
(Table I, Fig. 1). Generated TAT III complex of whole blood
stored at room temperature for 4 h corresponded to 14% of
the generated TAT III complex in PVC circuits that circu-
lated on the Hemobile (Table III). However, TAT III com-
plex of whole blood stored at room temperature for up to 4 h
did not change over time (Table II).
D. Hemolysis
Free Hb of whole blood stored at room temperature, 30 or
37 C, for up to 60 min did not change over time (Table I).
TABLE II. Activation markers of whole blood stored at room temperature for
1, 2, or 4-h.
Storage time (h)
Analyses (% baseline) 1 2 4 pa
Platelet count 97.16 8.27 1006 8.9 99.26 9.71 0.816
Mean platelet volume 1016 7.37 1026 6.5 99.86 5.91 0.913
Platelet-collagen binding 96.36 19.6 98.06 21.5 70.86 14.6 0.005
Thromboxane B2 1496 38.5 2366 68.8 3356 116 0.000
Complement complex C5b-9 95.86 9.15 98.16 8.08 1026 7.64 0.409
Elastase 1086 42.3 1196 38.2 1526 31.7 0.005
Thrombin-antithrombin III 86.36 44.0 1016 55.4 2206 170 0.086
Free hemoglobin 80.06 29.8 92.46 36.1 94.86 25.7 0.582
aPaired samples t-test between baseline and 4 h of storage.
FIG. 2. Influences of whole blood storage at room temperature on platelet-
collagen binding, thromboxane B2, and elastase. (a) Platelet-collagen bind-
ing, (b) thromboxane B2, and (c) elastase. *p< 0.05 compared with the
baseline (0 h).
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Generated free Hb of whole blood stored at room tempera-
ture for 4 h corresponded to 38% of the generated free Hb in
PVC circuits that circulated on the Hemobile (Table III).
However, free Hb of whole blood stored at room temperature
for up to 4 h did not change over time (Table II).
IV. DISCUSSION
The aim of this study was to describe the influence of
storage time and temperature on the basic hemocompatibility
variables: platelet function, inflammatory response, coagula-
tion, and hemolysis in whole blood prior to hemocompat-
ibility testing. First, we determined the effect of storage
temperature—a low temperature is known to induce several
platelet changes;15 therefore, we studied the temperature
effects between room temperature and 37 C. At room tem-
perature, none of the parameters changed up to 60 min of
storage time. However, storage at 30 or 37 C increased
blood activation after 60min. These data clearly indicated
that storage at room temperature was preferable. To obtain
further insight into the influence of prolonged storage at
room temperature, the parameters described earlier were
also analyzed on whole blood stored at room temperature for
1, 2, or 4 h. Platelet count, MPV, complement complex C5b-
9, TAT III complex, and free Hb were not influenced by stor-
age at room temperature after 4 h as compared to baseline.
However, PLT-collagen binding decreased during 4 h of
storage at room temperature, TXB2 already increased after
1 h of storage at room temperature, and elastase increased
during 4 h of storage at room temperature. Generated throm-
boxane B2, complement C5b-9 and TAT III complex in
stored whole blood after 4 h were only 9%, 0.1%, and 14%
of the generated concentrations in circulated PVC circuits,
respectively. However, generated elastase and free Hb in
stored whole blood after 4 h were 87% and 38% of the gener-
ated concentrations in circulated PVC circuits, respectively.
However, as described earlier, free Hb did not change over
time. Therefore, these results indicate that storage at room
temperature does affect, in particular, platelets and white
blood cells.
Blood activation can have a great impact on the reliability
of blood tests, especially during hemocompatibility testing.
For instance, the use of already activated blood during
hemocompatibility testing could result in an underestimation
of blood activation initiated by the biomaterial of interest,
due to possible exhaustion of activation products. On the
other hand, it could intensify blood activation initiated by
the biomaterial, resulting in an overestimation of blood acti-
vation. Braune et al. already described the influences of
citrated whole blood and PRP storage times on platelet-
morphology and function and stated that platelet morphol-
ogy and function, particularly platelet reactivity to adherent
or soluble agonists, changed rapidly outside the vascular sys-
tem.8 Yang et al. reported the stability of complement bio-
markers in whole blood containing citrate or EDTA.9
However, in serum without anticoagulant, increased comple-
ment activation was observed during 4 h of storage, which
can be explained by the presence of complement cofactors:
Ca2þ and Mg2þ ions. Likewise, in heparinized blood, the
complement system is also prone to activation.
Our findings indicate that activation of platelets already
takes place after 1 h of storage at room temperature.
Furthermore, our findings indicate that reduction of platelet
binding to collagen and activation of white blood cells takes
place after 4 h. Therefore, our findings advocate hemocom-
patibility tests to be initiated well within 4 h of blood collec-
tion. However, several other arguments can be raised that
allow the use of 4 h old blood. First, a baseline can be col-
lected just prior to the use of stored blood. Second, during
biocompatibility testing, reference materials should always
be tested with the same blood as the material of interest to
be able to eliminate donor variability. Third, the activation
markers: TXB2, complement complex C5b-9, and TAT gen-
erated after 4 h of storage represent less than 15% of the gen-
erated concentrations after blood circulation in a PVC
circuit, indicating that blood after 4 h of storage still has the
capacity to respond to an activating surface. Furthermore, by
using a positive reference during in vitro circulations, higher
levels of activation markers can be achieved, resulting in an
even lower percentage of storage activation compared to
achievable activation during in vitro circulations.
Future studies may include further evaluation of 4 h
stored blood used for in vitro circulation and because hemo-
compatibility tests are also frequently performed on citrate-
anticoagulated blood, future studies may also include the
TABLE III. Generated activation markers of stored whole blood and in vitro circulations. PVC circuits: activation markers in whole blood before (baseline) and
after (circulated) in vitro circulation of hemocompatible PVC circuits at 37 C for 1 h; Storage: activation markers in whole blood before (baseline) and after
(stored) storage at room temperature for 4 h; TXB2, thromboxane B2; C5b-9, complement complex C5b-9; TAT III, thrombin-antithrombin III complex; and
Free Hb, free hemoglobin.
PVC circuits Storage
Analyses Baseline Circulated Increase (%) Baseline Stored Increase (%) DStorage/DPVC (%)
TXB2 (ng/ml) 9666 1439 264086 12996 2632 4756 98.8 15816 709 233 9
C5b-9 (ng/ml) 13.76 5.65 53.186 47.9 289 22.96 22.1 23.016 20.44 0.36 0.1
Elastase (ng/ml) 19496 1160 29476 1319 51.1 19496 363 28126 968 44.2 87
TAT III (ng/ml) 13496 839 89936 8634 566 6596 1223 11796 2058 78.9 14
Free Hb (%) 0.106 0.03 0.256 0.14 159 0.036 0.03 0.046 0.03 60.4 38
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effects of storage time and temperature before initiation of
hemocompatibility tests using citrate-anticoagulated blood.
V. CONCLUSION
While it has previously been stated that hemocompat-
ibility of blood contacting medical devices should be thor-
oughly tested before certification,1 requirements regarding
the quality of blood used during hemocompatibility tests are
still in their infancy. As part of the quality of blood used dur-
ing hemocompatibility tests, information in relation to the
effects of time and temperature between blood collection
and hemocompatibility testing is still lacking. We observed
that storage at room temperature for up to 4 h does affect in
particular platelets and white blood cells. Although platelet
activation and platelet function were moderately affected,
white blood cell activation was similar to the activation
measured in blood which had been circulated in PVC cir-
cuits. Stationary storage of whole blood at room temperature
up to 4 h before initiation of hemocompatibility tests seems
unfavorable. Therefore, we propose hemocompatibility tests
to be initiated well within 4 h of blood collection, preferably
within 2 h of blood collection.
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